MSF launches patent opposition database to aid pharmaceutical protestors

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

MSF launches patent opposition database to aid pharmaceutical protestors

Health activists who want to challenge patents given to drugs companies have been given a new tool to make the process easier

Médecins Sans Frontières has today launched a database enabling activists to share information and experiences about opposing patents using one central portal.

The unveiling of the Patent Opposition Database comes 10 years after a landmark decision by Thailand's Central Intellectual Property and International Trade Court to overturn the patent on then-key HIV drug didanosine, after a patent opposition was filed by AIDS Access Foundation and three Thai people living with HIV.

The database contains a searchable listing of 45 patent oppositions relating to key medicines and more than 200 other supporting documents that will aid in the building of future patent oppositions.

In particular it provides a simple guide to legislation covering patent opposition and the processes involved in challenging a patent at the pre-grant or post-grant stage.

It also links to copies of opposition documents that have been filed in countries including Brazil, India and Thailand and calls for users to submit prior art documents that activists in other parts of the world can use for their own opposition applications.

“It’s a myth that every patent application that is filed is valid,” said Michelle Childs, Director of Policy Advocacy for MSF’s Access Campaign. “When you look closely, a patent application may fail one or more of the legal tests it needs to pass. The idea behind this database is to help civil society and patient groups stop unwarranted patents from blocking people’s access to more affordable medicines.”

MSF pointed to a number of cases in which patient groups have already challenged pharmaceutical patents. In India, for example, groups successfully challenged a patent application for the HIV fixed-dose-combination zidovudine/lamivudine on the grounds that it was not a new invention, but simply the combination of two existing drugs.

After that, the Cancer Patient Aid Association filed a pre-grant opposition to an application made by Novartis, which was seeking patent protection for the salt form of imatinib, the active ingredient in its cancer-treating drug Glivec. India’s Supreme Court is now considering whether the country’s patent office was right to refuse to grant Novartis a patent.

more from across site and SHARED ros bottom lb

More from across our site

Eva-Maria Strobel reveals some of the firm’s IP achievements and its approach to client relationships
Lateral hires at Thompson Hine and Pierson Ferdinand said they were inspired by fresh business opportunities and innovative strategies at their new firms
The launch of a new IP insurance product and INTA hiring a former USPTO commissioner were also among the top talking points this week
The firm explains how it secured a $170.6 million verdict against the government in a patent dispute surrounding airport technology, and why the case led to interest from other inventors
Developments of note included the court partially allowing a claim concerning confidentiality clubs and a decision involving technology used in football matches
The firm said adding capability in the French capital completes its coverage of all major patent litigation jurisdictions as it strives for UPC excellence
Marc Fenster explains how keeping the jury focused on the most relevant facts helped secure a $279m win for his client against Samsung
Clients are divided on what externally funded IP firms bring to the table, so those firms must prove why the benefits outweigh the downsides
Rahul Bhartiya, AI coordinator at the EUIPO, discusses the office’s strategy, collaboration with other IP offices, and getting rid of routine tasks
A boom in transactional work and a heightened awareness of IP have helped boost revenue for the rebranded commercial services team
Gift this article